Medicine and Dentistry
Tofacitinib
100%
Combination Therapy
83%
Host
66%
Sterilization
66%
Clearance
50%
Tuberculosis
50%
Mycobacterium Tuberculosis
50%
Janus Kinase
33%
Therapeutic Procedure
33%
Anti-Inflammatory Drug
33%
Macrophage
33%
Immunity
16%
Treatment Duration
16%
Immune Response
16%
Cytokine
16%
Infection
16%
Human Immunodeficiency Virus
16%
Granulomatous Inflammation
16%
Chemotherapeutic Agent
16%
Drug
16%
Tuberculosis Treatment
16%
Aptitude
16%
Survival
16%
INIS
mice
66%
therapy
66%
host
66%
mycobacterium tuberculosis
66%
clearance
50%
tuberculosis
50%
humans
33%
inflammation
33%
kinases
33%
sterilization
33%
drugs
16%
strains
16%
cytokines
16%
macrophages
16%
immunity
16%
viruses
16%
acceleration
16%
Immunology and Microbiology
Tofacitinib
100%
Mycobacterium Tuberculosis
66%
Clearance
50%
Host
50%
Mouse
33%
Immunity
16%
Bagg Albino Mouse
16%
Host Immune Response
16%
Human Immunodeficiency Virus
16%
Mouse Model
16%
Proinflammatory Cytokine
16%
Human
16%
Acceleration
16%
C3HeB/Fe Mouse
16%
Survival
16%
Aptitude
16%
Granuloma
16%
Pharmacology, Toxicology and Pharmaceutical Science
Tofacitinib
100%
Host
66%
Mycobacterium Tuberculosis
50%
Tuberculosis
50%
Janus Kinase
33%
Mouse
33%
HIV
16%
Infection
16%
Mouse Model
16%
Cytokine
16%
Human
16%
Bagg Albino Mouse
16%
Drug
16%
Granulomatous Inflammation
16%
Survival
16%
C3HeB/Fe Mouse
16%